In silico design and experimental validation of a multi-epitope vaccine candidate against Helicobacter hepaticus associated chronic liver inflammation - Top-Institutions - MDSpire

In silico design and experimental validation of a multi-epitope vaccine candidate against Helicobacter hepaticus associated chronic liver inflammation

  • By

  • Liangliang Weng

  • Zhang Huijie

  • Ni Man

  • Liu Yang

  • Min Cao

  • April 30, 2026

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Hepatology
    • Vaccine Research

  • #2

    Harvard Medical School / Massachusetts General Hospital
    Harvard Medical School / Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Immunology
    • Hepatology
    • Infectious Diseases
    • Vaccine Development

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Hepatology
    • Infectious Diseases
    • Immunology
    • Vaccine Research

  • #4

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Vaccine Development

  • #5

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Immunology
    • Hepatology
    • Infectious Diseases
    • Vaccine Research

Original Source(s)

In silico design and experimental validation of a multi-epitope vaccine candidate against Helicobacter hepaticus associated chronic liver inflammation

  • by Liangliang Weng, Zhang Huijie, Ni Man, Liu Yang, Min Cao

  • April 30, 2026

Related Content

Tzield Approval Expands to Younger Patients

First disease-modifying option available for children as young as 1 year with stage 2 type 1 diabetes

Rapid AST Speeds Care, Not Outcomes

Faster antibiotic optimization may still support use of rapid testing, particularly when paired with stewardship.

NASA's Future Space Habitation Strategies Must Emphasize Immunology and Infectious Disease Management